Poliomyelitis Clinical Trial
Official title:
Serological Survey on Monitoring the Population Immunity and Positive Rate After Vaccination of Inactivated Poliovirus Vaccine
The Purpose of this study is to assess the seroconversion using inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV) sequential schedule in pilot areas where IPV was phased introduced into national immunization program (NIP) in China.
Objective:
1. To evaluate the seroprotection rates after the 3 doses of primary polio vaccination
among age eligible children in pilot areas where the IPV was introduced into NIP;
2. To evaluate the seroprotection rates after different dose(s) of polio vaccine(s) using
sequential schedule.
Sample size:752
1. Jilin shall select 120 subjects to collect blood samples for evaluation of immune
response,of whom 90 will be given OPV as second vaccine and 30 will be given IPV as
second vaccine
2. Hubei shall select 132 subjects to collect blood samples for evaluation of immune
response,of whom 102 will be given OPV as second vaccine and 30 will be given IPV as
second vaccine
3. Ningxia shall select 260 subjects to collect blood samples for evaluation of immune
response. The subject will be divided into 5 groups.
4. In Guangdong province,120 children will be selected as subjects , of whom 80 children
will be given OPV as first vaccine and 40 children will be given IPV as first vaccine.
5. Tianjin shall select 120 subjects to collect blood samples for evaluation of immune
response, of whom 80 will be given OPV as second vaccine and 30 will be given IPV as
second vaccine
Organization Chart of the Study:
- Chinese Centers for Disease Control and Prevention (China CDC) lead the overall study,
and be responsible for the study design, supervise the five selected provinces, conduct
field monitor, data analysis and result distribution and explanation.
- The five pilot Provincial CDCs conduct the supervision and monitoring of 1-2 counties
CDCs in each of pilot province.
- The County CDCs organize several vaccination clinics to recruit the subjects who meet
the Inclusion criteria.
Quality Assurance Plan:
- China CDC and provincial CDC will monitor and supervise the field work, ensure the
quality of the study.
- County CDCs organize vaccination clinics to service the subjects receiving timely polio
vaccines in accordance with the immunization schedule, and that the blood samples are
collected in accordance with the required timeline in difference groups.
- Clinic doctors will communicate and explain the purpose and procedure of the survey to
parents, and the signed informed consent from by parents will be obtained before the
children participate the study.
- The target drop-out rate of subjects without the second blood samples in each province
should be less than 10%.
- The samples will be tested for polio antibody in a qualified laboratory, which should be
a World Health Organization certified polio network laboratory in China.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04989231 -
An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses
|
||
Completed |
NCT00352963 -
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).
|
Phase 3 | |
Recruiting |
NCT03890497 -
Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV When Administered at 9-13 Months of Age in Bangladesh
|
Phase 4 | |
Completed |
NCT00753649 -
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants
|
Phase 4 | |
Completed |
NCT04693286 -
Clinical Trial of Novel OPV2 Vaccine
|
Phase 2 | |
Completed |
NCT02847026 -
Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study
|
Phase 4 | |
Completed |
NCT02189811 -
Polio End-game Strategies - Poliovirus Type 2 Challenge Study
|
Phase 4 | |
Completed |
NCT01444781 -
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants
|
Phase 3 | |
Completed |
NCT01214889 -
Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.
|
Phase 3 | |
Completed |
NCT00879827 -
Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants
|
Phase 3 | |
Completed |
NCT01457495 -
Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly
|
Phase 2 | |
Completed |
NCT02853929 -
Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
|
Phase 4 | |
Completed |
NCT03614702 -
Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV
|
Phase 3 | |
Terminated |
NCT04063150 -
Immunogenicity of Intramuscular and Intradermal IPV
|
Phase 4 | |
Completed |
NCT04614597 -
A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China
|
||
Completed |
NCT03239496 -
A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV
|
Phase 3 | |
Completed |
NCT04544787 -
A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates
|
Phase 2 | |
Completed |
NCT02985320 -
Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine
|
Phase 1/Phase 2 | |
Completed |
NCT02274285 -
DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants
|
Phase 3 | |
Completed |
NCT02291263 -
Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine
|
Phase 3 |